Robert W. Rapkins
YOU?
Author Swipe
View article: P11.21.A LONG-TERM SURVIVAL WITH IDH WILDTYPE GLIOBLASTOMA: FIRST RESULTS FROM THE ETERNITY BRAIN TUMOR FUNDERS’ COLLABORATIVE CONSORTIUM (EORTC 1419)
P11.21.A LONG-TERM SURVIVAL WITH IDH WILDTYPE GLIOBLASTOMA: FIRST RESULTS FROM THE ETERNITY BRAIN TUMOR FUNDERS’ COLLABORATIVE CONSORTIUM (EORTC 1419) Open
BACKGROUND Median survival with glioblastoma remains in the range of 12 months on population levels. Only few patients survive for more than 5 years. Patient and disease features associated with long-term survival remain poorly defined. ME…
View article: Supplementary Tables from SNP rs16906252C>T Is an Expression and Methylation Quantitative Trait Locus Associated with an Increased Risk of Developing <i>MGMT</i>-Methylated Colorectal Cancer
Supplementary Tables from SNP rs16906252C>T Is an Expression and Methylation Quantitative Trait Locus Associated with an Increased Risk of Developing <i>MGMT</i>-Methylated Colorectal Cancer Open
Supplementary Table 1. Statistical comparisons between the methylation status of the MGMT promoter within colorectal carcinoma (CRC) and clinicopathological features, molecular features of tumors, and rs16906252C>T genotype in cases from t…
View article: Supplementary Methods from SNP rs16906252C>T Is an Expression and Methylation Quantitative Trait Locus Associated with an Increased Risk of Developing <i>MGMT</i>-Methylated Colorectal Cancer
Supplementary Methods from SNP rs16906252C>T Is an Expression and Methylation Quantitative Trait Locus Associated with an Increased Risk of Developing <i>MGMT</i>-Methylated Colorectal Cancer Open
Supplementary methods providing additional technical detail for methods that is relevant only to those who wish to repeat them exactly
View article: Supplementary Figures from SNP rs16906252C>T Is an Expression and Methylation Quantitative Trait Locus Associated with an Increased Risk of Developing <i>MGMT</i>-Methylated Colorectal Cancer
Supplementary Figures from SNP rs16906252C>T Is an Expression and Methylation Quantitative Trait Locus Associated with an Increased Risk of Developing <i>MGMT</i>-Methylated Colorectal Cancer Open
Supplementary Figure 1. Allele quantification assays used to measure relative levels of mRNA expression at exonic SNPs within MGMT. Supplementary Figure 2. Allelic expression ratios of MGMT transcripts in the normal colorectal mucosa (NCM)…
View article: Data from SNP rs16906252C>T Is an Expression and Methylation Quantitative Trait Locus Associated with an Increased Risk of Developing <i>MGMT</i>-Methylated Colorectal Cancer
Data from SNP rs16906252C>T Is an Expression and Methylation Quantitative Trait Locus Associated with an Increased Risk of Developing <i>MGMT</i>-Methylated Colorectal Cancer Open
Purpose: Methylation of the MGMT promoter is the major cause of O6-methylguanine methyltransferase deficiency in cancer and has been associated with the T variant of the promoter enhancer SNP rs16906252C>T. We sought evidence for an associ…
View article: Data from SNP rs16906252C>T Is an Expression and Methylation Quantitative Trait Locus Associated with an Increased Risk of Developing <i>MGMT</i>-Methylated Colorectal Cancer
Data from SNP rs16906252C>T Is an Expression and Methylation Quantitative Trait Locus Associated with an Increased Risk of Developing <i>MGMT</i>-Methylated Colorectal Cancer Open
Purpose: Methylation of the MGMT promoter is the major cause of O6-methylguanine methyltransferase deficiency in cancer and has been associated with the T variant of the promoter enhancer SNP rs16906252C>T. We sought evidence for an associ…
View article: Supplementary Tables from SNP rs16906252C>T Is an Expression and Methylation Quantitative Trait Locus Associated with an Increased Risk of Developing <i>MGMT</i>-Methylated Colorectal Cancer
Supplementary Tables from SNP rs16906252C>T Is an Expression and Methylation Quantitative Trait Locus Associated with an Increased Risk of Developing <i>MGMT</i>-Methylated Colorectal Cancer Open
Supplementary Table 1. Statistical comparisons between the methylation status of the MGMT promoter within colorectal carcinoma (CRC) and clinicopathological features, molecular features of tumors, and rs16906252C>T genotype in cases from t…
View article: Supplementary Figures from SNP rs16906252C>T Is an Expression and Methylation Quantitative Trait Locus Associated with an Increased Risk of Developing <i>MGMT</i>-Methylated Colorectal Cancer
Supplementary Figures from SNP rs16906252C>T Is an Expression and Methylation Quantitative Trait Locus Associated with an Increased Risk of Developing <i>MGMT</i>-Methylated Colorectal Cancer Open
Supplementary Figure 1. Allele quantification assays used to measure relative levels of mRNA expression at exonic SNPs within MGMT. Supplementary Figure 2. Allelic expression ratios of MGMT transcripts in the normal colorectal mucosa (NCM)…
View article: Supplementary Methods from SNP rs16906252C>T Is an Expression and Methylation Quantitative Trait Locus Associated with an Increased Risk of Developing <i>MGMT</i>-Methylated Colorectal Cancer
Supplementary Methods from SNP rs16906252C>T Is an Expression and Methylation Quantitative Trait Locus Associated with an Increased Risk of Developing <i>MGMT</i>-Methylated Colorectal Cancer Open
Supplementary methods providing additional technical detail for methods that is relevant only to those who wish to repeat them exactly
View article: The role of TP53 gain-of-function mutation in multifocal glioblastoma
The role of TP53 gain-of-function mutation in multifocal glioblastoma Open
Purpose The phenotypic and genotypic landscapes in multifocal glioblastoma (MF GBM) cases can vary greatly among lesions. In a MF GBM patient, the rapid development of a secondary lesion was investigated to determine if a unique genetic si…
View article: Circulating cell-free DNA from plasma undergoes less fragmentation during bisulfite treatment than genomic DNA due to low molecular weight
Circulating cell-free DNA from plasma undergoes less fragmentation during bisulfite treatment than genomic DNA due to low molecular weight Open
DNA fragmentation during bisulfite treatment does not contribute to loss of sensitivity in methylation analysis of circulating DNA. The absence of DNA fragments below approximately 170 bases from agarose gel images of purified circulating …
View article: P04.16 TP53 mutations in codon 273 is predictive of overall survival in astrocytoma patients
P04.16 TP53 mutations in codon 273 is predictive of overall survival in astrocytoma patients Open
BACKGROUND Tumour Protein 53 (TP53) is a tumour suppressor gene that is mutated in at least 50% of human malignancies. The prevalence of TP53 mutation is much higher in astrocytomas with reports of up to 75% TP53 mutant cases. Rare cases o…
View article: A case study of a long-term glioblastoma survivor with unmethylated <i>MGMT</i> and hypermutated genotype
A case study of a long-term glioblastoma survivor with unmethylated <i>MGMT</i> and hypermutated genotype Open
Effective treatments that extend survival of malignant brain tumor glioblastoma (GBM) have not changed in more than a decade; however, there exists a minority patient group (<5%) whose survival is longer than 3 yr. We herein present a case…
View article: EPEN-01. CHARACTERIZATION AND DRUG TESTING IN PRECLINICAL EPENDYMOMA MODELS
EPEN-01. CHARACTERIZATION AND DRUG TESTING IN PRECLINICAL EPENDYMOMA MODELS Open
INTRODUCTION: Currently there are no effective chemotherapeutic treatments for ependymomas, with maximal surgical excision and radiotherapy the mainstays of treatment. The identification of at least 9 molecularly distinct subgroups, sugges…
View article: CBMT-45. A NOVEL C-CIRCLE ASSAY FOR DETECTING ALTERNATIVE LENGTHENING OF TELOMERES (ALT) MECHANISMS
CBMT-45. A NOVEL C-CIRCLE ASSAY FOR DETECTING ALTERNATIVE LENGTHENING OF TELOMERES (ALT) MECHANISMS Open
Low-grade gliomas, in particular astrocytoma, have been previously reported to harbor Alternative lengthening of telomere (ALT) to maintain their telomeres to aid sustained replication. Targeting genetic pathways specific to ALT mechanism …
View article: PATH-11. TRANSLATING GENOMIC DATA OF GLIOBLASTOMA INTO CLINICAL PRACTICE: A CASE STUDY
PATH-11. TRANSLATING GENOMIC DATA OF GLIOBLASTOMA INTO CLINICAL PRACTICE: A CASE STUDY Open
Glioblastoma (GBM), a malignant brain tumour that occur in adults and children, represents a major challenge for treatment. Tumor heterogeneity has been shown to contribute to this problem. The aim of this study was to overcome this issue …
View article: PDTM-44. INTRACRANIAL EPENDYMOMA: DEVELOPING PRECLINICAL MODELS AND IDENTIFYING NOVEL TREATMENTS
PDTM-44. INTRACRANIAL EPENDYMOMA: DEVELOPING PRECLINICAL MODELS AND IDENTIFYING NOVEL TREATMENTS Open
INTRODUCTION: Clinical trials have not identified any effective chemotherapeutic treatments for intracranial ependymomas. This failure is partially explained by the recent identification of 6 molecularly distinct intracranial subgroups. Wh…
View article: P08.22 Targeting glioblastoma mitochondrial metabolism to inhibit cell proliferation & tumor growth
P08.22 Targeting glioblastoma mitochondrial metabolism to inhibit cell proliferation & tumor growth Open
\nBackground: Abrogating tumor mitochondrial metabolism by targeting the mitochondria and inhibiting the mTOR pathway is an effective mechanism to impede glioblastoma growth. Inhibiting the mitochondrial activity with an organic arsenide c…
View article: Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma
Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma Open
Our results demonstrate preclinical efficacy of targeting PARP at multiple levels and provide a new approach for the treatment of MGMT unmethylated GBM.
View article: EXTH-20. TARGETING GLIOBLASTOMA METABOLISM THROUGH mTOR AND MITOCHONDRIAL INHIBITION
EXTH-20. TARGETING GLIOBLASTOMA METABOLISM THROUGH mTOR AND MITOCHONDRIAL INHIBITION Open
Poster presented at the 21st Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology; November 17-20, 2016; Scottsdale, Arizona. Abstract available at https://doi.org/10.1093/neuonc/now212.264
View article: TMOD-14. ESTABLISHMENT AND MOLECULAR CHARACTERIZATION OF PATIENT DERIVED CELL LINES FROM LOW GRADE GLIOMA
TMOD-14. ESTABLISHMENT AND MOLECULAR CHARACTERIZATION OF PATIENT DERIVED CELL LINES FROM LOW GRADE GLIOMA Open
Low Grade Gliomas (LGGs), although they are rare in incidence, usually affect younger adults (20-40 years of age) with patient survival varying between 5-15 years. The in vitro culturing of LGG and subsequent mutational profiling would be …
View article: SNP rs16906252C&gt;T Is an Expression and Methylation Quantitative Trait Locus Associated with an Increased Risk of Developing <i>MGMT</i> -Methylated Colorectal Cancer
SNP rs16906252C>T Is an Expression and Methylation Quantitative Trait Locus Associated with an Increased Risk of Developing <i>MGMT</i> -Methylated Colorectal Cancer Open
Purpose: Methylation of the MGMT promoter is the major cause of O6-methylguanine methyltransferase deficiency in cancer and has been associated with the T variant of the promoter enhancer SNP rs16906252C>T. We sought evidence for an ass…